Vitestro achieves CE marking for autonomous blood drawing device
Evidence notes
- Vitestro announced CE marking for its autonomous blood drawing device under the European Medical Device Regulation.
- The approval cleared the device for commercial use across the European Union.
- The company said several devices had already been ordered and planned a limited market release over the following months.
Company context
Develops autonomous robotic blood collection systems for clinical settings. Its Aletta platform is an autonomous robotic phlebotomy device that uses multimodal imaging, robotics, and AI to identify veins, insert the needle, collect diagnostic blood tubes, and complete the venous blood draw workflow. The company is focused on hospital and outpatient diagnostic workflows, with CE-marked deployment in Europe and U.S. regulatory work underway.